||Cadherin 1 antibody; CD324 antigen antibody
||E-Cadherin is a key cell adhesion molecule located at adherens junctions (AJs) and undergoes endocytosis when AJs are disrupted by the action of extracellular signals. It is a member of cadherin family that includes cadhesin repeats of approximately 100 residues in their extracellular domian. E-Cadherin plays a crucial role in the maintenance of the epithelial junctional complex and is an important molecule in maintaining epithelial integrity. The expression of E-Cadherin might be associated with the invasive potential of epithelial neoplasms. Defects in E-Cadherin are a cause of gastric cancer, also known as hereditary familial diffuse gastric cancer (HDGC).
GenScript E-Cadherin Antibody is developed in rabbit using a KLH-coupled synthetic peptide within residues 650–700 of human E-Cadherin (Swiss Prot: P12830).
||0.5 mg/ml, lyophilized with PBS, pH 7.4, containing 0.02% sodium azide
||Reconstitute the lyophilized powder with deionized water (or equivalent) to an antibody concentration of 0.5 mg/ml.
||GenScript E-Cadherin Antibody detects human and mouse endogenous levels of E-Cadherin. It is predicted to react with rat E-Cadherin protein according to sequence homology.
Positive Control: HepG2 and NIH/3T3
||The antibody is stable in lyophilized form if stored at -20°C or below. The reconstituted antibody can be stored for 2-3 weeks at 2-8°C. For long term storage, aliquot and store at -20°C or below. Avoid repeated freezing and thawing cycles.
|Working concentrations for specific applications should be determined by the investigator. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product.
Western blot: 0.5-1 µg/ml
Flow cytometry: 1-3 µg for 1 x 106 cells
Other Applications: user-optimized
Western Blot Protocol(pdf)
Dong P., et al. Mutant P53 Gain-Of-Function Induces Epithelial-Mesenchymal Transition Through Modulation Of The Mir-130B-Zeb1 Axis. Oncogene. 2013 Jul;32(27):3286-95.
Dong P., et al. Identification of KLF17 as a novel epithelial to mesenchymal transition inducer via direct activation of TWIST1 in endometrioid endometrial cancer. Carcinogenesis. 2013 Dec.
Erin N., et al. Differential characteristics of heart, liver, and brain metastatic subsets of murine breast carcinoma. Breast Cancer Res Treat. 2013 Jun;139(3):677-689.
Y Konno, et al. MicroRNA-101 targets EZH2, MCL-1 and FOS to suppress proliferation, invasion and stem cell-like phenotype of aggressive endometrial cancer cells. Oncotarget. 2014Aug.;5(15):6049-62